Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

Preclinical application of 188Re-Tin colloid for treatment of mouse tumor model with peritoneal effusion

  • Jin, Yong Nan (Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine) ;
  • Lee, Yong Jin (Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine) ;
  • Kim, Young Joo (Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine) ;
  • Lee, Yun-Sang (Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine) ;
  • Jeong, Jae Min (Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine)
  • Received : 2017.12.08
  • Accepted : 2017.12.24
  • Published : 2017.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Re-188 is an excellent and practical radioisotope produced by W-188/Re-188-generator for therapy. We prepared Re-188-tin colloid for therapy of various diseases and tried to treat peritoneal effusion in animal model. Sarcoma-180 cells were injected into ICR mice to induce peritoneal effusion and the mice were grown for 3 d. Re-188-tin colloids (0.25, 0.5, and 1 mCi/mL per 30 g body weight) were injected into the mice and the mice were grown for 90 d. Planar gamma scintigraphy showed even distribution of Re-188-tin colloid radioactivity. Bax expression was found to be dose dependent to Re-188-tin colloid. Normal saline treated group showed the shortest survival time. Among the treated groups, 0.5 mCi dose group showed the longest survival time. In conclusion, Re-188-tin colloid was prepared successfully and showed the feasibility to use as a peritoneal effusion treatment in mice.

Keywords

References

  1. Parsons SL, Watson SA, Stelle RJC. Malignant ascites. Br J Surg 1996;83: 6-14. https://doi.org/10.1002/bjs.1800830104
  2. Yazdi GP, Miedema BW, Humphrey LJ. High mortality after abdominal operation in patients with large-volume malignant ascites. J Surg Oncol 1996;62:93-96. https://doi.org/10.1002/(SICI)1096-9098(199606)62:2<93::AID-JSO4>3.0.CO;2-L
  3. Muller JH. Weitere Entwicklung der Therapie von peritoneal-carcinosen bei Ovarialcarcinom mit kunstilicher radioactivitat ($Au-^{198}$). Gynaecologia 1950;129:289-294.
  4. Rogoff EE, Romano R, Hahn EW. The prevention of Ehrlich ascites tumor using intraperitoneal colloidal 198Au. Dose vs. size of inoculum. Radiology 1975;114:225-226. https://doi.org/10.1148/114.1.225
  5. Jacobs ML. Radioactive colloidal chromic phosphate to control pleural effusion of ascites. J Am Med Assoc 1958;166:597-599. https://doi.org/10.1001/jama.1958.02990060035008
  6. Boye E, Lindegaard MW, Paus E, Skretting A, Davy M, Jakobsen E. Whole-body distribution of radioactivity after intraperitoneal administration of $^{32}P$ colloids. Br J Radiol 1984;57:395-402. https://doi.org/10.1259/0007-1285-57-677-395
  7. Balink H, Sijmons EA Zonnenberg BA, De Klerk JM. Repetitive phosphorus-32 peritoneal instillations in a patient with malignant ascites. Clin Nucl Med 2003;28:545-547. https://doi.org/10.1097/00003072-200307000-00002
  8. Knapp FF Jr. Rhenium-188 - a generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm 1998;13: 337-349. https://doi.org/10.1089/cbr.1998.13.337
  9. Jeong JM, Chung JK. Therapy with 188Re-labeled raidiopharmaceuticals: an overview of promising results from initial clinical trials. Cancer Biother Radiopharm 2003;18:707-717. https://doi.org/10.1089/108497803770418256
  10. Jeong JM, Lee YJ, Kim EH, Chang YS, Kim YJ, Son M, Lee DS, Chung JK, Lee MC. Preparation of (188) Re-labeled Re-labeled paper for treating of skin cancer. Appl Radiat Isot 2003;58:551-555. https://doi.org/10.1016/S0969-8043(03)00063-0
  11. Jeong JM, Kim YJ, Lee YS,Ko JI, Son M, Lee DS, Chung JK, Park JH, Lee MC. Lipiodol solution of a lipophilic agent, (188)Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001;28:197-204. https://doi.org/10.1016/S0969-8051(00)00208-0
  12. Lee YS, Jeong JM, Kim YJ, Chung JW, Park JH, Suh YG, Lee DS, Chung JK, Lee MC. Synthesis of 188 Re-labeled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002;23:237-242. https://doi.org/10.1097/00006231-200203000-00006
  13. Knapp FF, Callahan AP, Beets AL, Mirzadeh S, Hsieh BT. Processing of reactor-produced $^{188}W$ for fabrication of clinical scale alumina-based $^{188}W$/$^{188}Re$ generators. Appl Radiat Isot 1994;45:1123-1128. https://doi.org/10.1016/0969-8043(94)90026-4
  14. Lee EB, Shin KC, Lee YJ, Cheon GJ, Jeong JM, Son MW, Song YW. 188Re-tin-colloid as a new therapeutic agent for rheumatoid arthritis. Nucl Med Commun 2003;24:689-696. https://doi.org/10.1097/00006231-200306000-00012
  15. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grunwald F, Knapp FF Jr, Biersack HJ. Dose escalation study with r rhenium-188hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000;27:123-130. https://doi.org/10.1007/s002590050017
  16. Savio E, Guadiano J, Robles AM, Balter H, Paolino A, Lopez A, Hermida JC, De Marco E, Martinez G, Osinaga E, Knapp FF Jr. Re-HEDP: Pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose. BMC Nucl Med 2001;1:2. https://doi.org/10.1186/1471-2385-1-2
  17. Lambert B, Bacher K, Keukeleire KD, Smeets P, Colle I, Jeong JM, Thierens H, Troisi R, De Vos F, Van de Wiele C. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis. J Nucl Med 2005;46:1326-1332.
  18. Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong JM, Dierckx RA, Van de Wiele C, Thierens H, De Vos F. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.. J Nucl Med 2005; 46:60-66.
  19. Lambert B, Bacher K, Defreyne L, Van Vlierberghe H, Jeong JM, Wang RF, van Meerbeeck J, Smeets P, Troisi R, Thierens H, De Vos F, Van de Wiele C. (188)Re- HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. Eur J Nucl Med Mol Imaging 2006;33:344-352. https://doi.org/10.1007/s00259-005-1954-1
  20. Wang S-J, Lin W-Y, Hsieh B-T, Shen LH, Tsai ZT, Ting G, Knapp FF Jr. Rhenium-188 sulfur colloid as a radiation synovectomy agent. Eur J Nucl Med 1995;22:505-507. https://doi.org/10.1007/BF00817272
  21. Jeong JM, Lee YJ, Kim YJ, Chang YS, Lee DS, Chung JK, Song YW, Lee MC. Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid. Appl Radiat Isot 2000;52:851- 855 https://doi.org/10.1016/S0969-8043(99)00131-1
  22. Chen FD, Hsieh BT, Wang HE, Ou YH, Yang WK, Whang- Peng J, Liu RS, Knapp FF, Ting G, Yen SH. Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals. Nucl Med Biol 2001;28:835-844. https://doi.org/10.1016/S0969-8051(01)00244-X
  23. Lee EB, Shin KC, Lee YJ, Cheon GJ, Jeong JM, Son MW, Song YW. 188Re-tin-colloid as a new therapeutic agent for rheumatoid arthritis. Nucl Med Commun 2003;24:689-696. https://doi.org/10.1097/00006231-200306000-00012
  24. Croll MN, Brady LW. Intracavitary uses of colloids. Semin Nucl Med 1979;9:108-113. https://doi.org/10.1016/S0001-2998(79)80042-2